Tarceva linked with two patient deaths

Two patients died following liver damage related to taking the cancer drug Tarceva, according to a letter the FDA posted. The two patients were involved in a study with 13 other patients that the companies believed had moderate liver problems, but it turns out the problems were severe.  They died within one month of completing treatment. There were 36 participants in the study in total.

OSI Pharmaceuticals manufactures the medication, which aims to treat lung and pancreatic cancers. Its partner, Genentech, sells Tarceva.

As a result, the drug now has stronger liver toxicity warnings on its label.  The companies sent a letter to physicians yesterday that emphasizes the importance of close monitoring of patients taking the drug if the patients have liver problems.

The FDA approved Tarceva in 2004.

- view the letter (.pdf)
- read the Business Week report
- see what News Day has to say

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.